The startup develops multi-functional electronic devices that utilize molecular testing to measure and analyze the chemical and biological composition of substances. These devices enable users to conduct home diagnostics and personalized testing, facilitating health optimization and illness prevention through precise molecular detection.
Funding
$2.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current laboratory blood testing methods can be inefficient, time-consuming, and require specialized equipment, limiting accessibility and delaying results for timely health management. Existing therapeutic drug monitoring (TDM) practices often rely on estimated drug levels, population-based dosing models, and reactive monitoring, leading to inaccurate dosing and potential adverse effects.
Solution
ZiO Health offers a pocket-sized, AI-driven point-of-care (POC) platform for rapid, lab-grade molecular testing and therapeutic drug monitoring (TDM). The platform combines proprietary biosensor technology with machine learning algorithms to provide quantitative results and personalized dosing information at the point of care. This enables proactive and precise drug management, enhancing treatment efficacy, minimizing toxicity, and reducing hospital stays. ZiO Health's technology supports both single-point and continuous monitoring across various clinical applications, including heart failure screening and management, antibiotic susceptibility testing, and precision dosing of medications like vancomycin and biologics. The platform aims to decentralize medical testing and health data, making it more accessible for proactive health management and decentralized clinical trials.
Target Audience
The primary target audience includes healthcare providers, pharmaceutical companies, and clinical researchers seeking to improve patient outcomes through rapid, accessible, and personalized molecular testing and therapeutic drug monitoring.
Features
- Proprietary pocket-sized biosensor technology for point-of-care molecular testing
- AI-driven algorithms for real-time results and personalized dosing models
- Capability to test both free and total drug levels for enhanced accuracy
- Support for single-point testing and continuous monitoring
- Applications for therapeutic drug monitoring (TDM) of various medications (e.g., vancomycin, anti-retrovirals, anti-epileptics, biologics)
- Potential to reduce hospital admissions and inappropriate drug use
- Integration with decentralized clinical trials for patient-centric drug development